Zealand Pharma CEO believes in firm's obesity efforts
Adam Steensberg, the CEO of Zealand Pharma, says that the firm’s three candidates within the indication make the firm an interesting player on the obesity market.
by christian bundgaard, translated by catherine brett
Private wealth manager Bernstein has previously predicted that the obesity market in the US could be worth up to DKK 500bn (USD 72bn) within ten years – and Zealand Pharma wants in.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma stock soars after selling insulin pump
For subscribers
.jpg&w=384&q=75)
